Q2 EPS Estimates for Veeva Systems Raised by Zacks Research

Veeva Systems Inc. (NYSE:VEEV) – Stock analysts at Zacks Research raised their Q2 2026 earnings per share (EPS) estimates for Veeva Systems in a report issued on Wednesday, March 26th. Zacks Research analyst R. Department now anticipates that the technology company will post earnings of $1.22 per share for the quarter, up from their prior forecast of $1.14. The consensus estimate for Veeva Systems’ current full-year earnings is $4.35 per share. Zacks Research also issued estimates for Veeva Systems’ Q3 2026 earnings at $1.33 EPS, Q4 2026 earnings at $1.31 EPS, Q1 2027 earnings at $1.32 EPS and Q2 2027 earnings at $1.35 EPS.

Other equities analysts have also issued research reports about the stock. Truist Financial lifted their price target on shares of Veeva Systems from $210.00 to $217.00 and gave the company a “hold” rating in a research report on Thursday, March 6th. Piper Sandler lifted their target price on shares of Veeva Systems from $280.00 to $290.00 and gave the stock an “overweight” rating in a report on Friday, December 6th. Morgan Stanley raised their price target on Veeva Systems from $195.00 to $201.00 and gave the company an “underweight” rating in a research report on Thursday, March 6th. Scotiabank lifted their price objective on Veeva Systems from $240.00 to $245.00 and gave the stock a “sector perform” rating in a research note on Thursday, March 6th. Finally, JPMorgan Chase & Co. increased their target price on Veeva Systems from $218.00 to $249.00 and gave the company a “neutral” rating in a research note on Thursday, March 20th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $256.52.

Veeva Systems Stock Performance

Shares of VEEV stock opened at $237.52 on Friday. The stock’s 50 day simple moving average is $231.27 and its 200 day simple moving average is $222.79. Veeva Systems has a twelve month low of $170.25 and a twelve month high of $258.93. The company has a market capitalization of $38.56 billion, a price-to-earnings ratio of 58.65, a PEG ratio of 1.89 and a beta of 0.88.

Institutional Investors Weigh In On Veeva Systems

A number of hedge funds and other institutional investors have recently bought and sold shares of VEEV. Principal Financial Group Inc. grew its holdings in shares of Veeva Systems by 138.9% during the third quarter. Principal Financial Group Inc. now owns 2,179,284 shares of the technology company’s stock worth $457,366,000 after purchasing an additional 1,267,061 shares during the last quarter. Raymond James Trust N.A. bought a new stake in Veeva Systems during the 3rd quarter worth about $231,000. Algert Global LLC increased its position in Veeva Systems by 64.0% in the 3rd quarter. Algert Global LLC now owns 2,254 shares of the technology company’s stock valued at $473,000 after acquiring an additional 880 shares in the last quarter. Centaurus Financial Inc. raised its stake in shares of Veeva Systems by 28.1% in the third quarter. Centaurus Financial Inc. now owns 1,335 shares of the technology company’s stock worth $280,000 after acquiring an additional 293 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Veeva Systems during the third quarter worth approximately $49,000. 88.20% of the stock is owned by institutional investors and hedge funds.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.